Ceftriaxone alone or in combination with antibiotics in the management of infection in cancer patients. A review of 41 clinical trials involving 7350 patient-episodes

Mario Venditti, P. Martino, C. Viscoli, J. Klastersky

Research output: Contribution to journalArticlepeer-review

Abstract

Empirical therapy with a broad-spectrum β-lactam and an aminoglycoside is the cornerstone of the management of patients with granulocytopenia and fever. These regimens are able to considerably lower mortality associated with serious infections; however, the optimal management of fever in these 'difficult to treat' patients remains controversial, with other factors such as cost-effectiveness becoming ever more important. The ideal antibiotic regimen for serious infections in cancer patients must therefore be effective in serious infections, but not be too expensive or inconvenient to use. This paper considers the evolution of this therapeutic intervention and reviews the opportunities available for once-daily therapy in treating infections associated with febrile neutropenia, with particular emphasis on the third generation cephalosporin, ceftriaxone. Ceftriaxone has highly favourable pharmacokinetics (half-life of 8 hours), which allow once-daily dosage regimens to be employed even in the most severe infections associated with cancer therapy.

Original languageEnglish
Pages (from-to)195-210
Number of pages16
JournalClinical Drug Investigation
Volume17
Issue number3
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Ceftriaxone alone or in combination with antibiotics in the management of infection in cancer patients. A review of 41 clinical trials involving 7350 patient-episodes'. Together they form a unique fingerprint.

Cite this